The FDA has approved Enbumyst, a nasal spray formulation of bumetanide, for the treatment of edema associated CHF, and hepatic and renal disease.

Eight African countries, including Uganda, Kenya and Tanzania, participated in the review and committed to fast-tracking national approvals within 90 days NEWS ANALYSIS | BY AGENCIES | Every year, ...

Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept.

Cingulate (CING) announced it has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, the ...

The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of nine new drugs, including three anti-inflammation fixed dose combinations (FDCs) and six antidiabetic combinations ...

Piramal Pharma Solutions, a global CDMO, has acquired a Korsch XM-12 bilayer tablet press at its drug product facility in ...

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

Pharmacy leaders call for action to prevent hold-ups which can occur when stocks run out as pharmacists do not currently have the power to alter a prescription ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the ...

Patients with Graves disease who taper methimazole to a maintenance dose of 1.25 mg/day before discontinuing the drug experience improved remission rates compared to those on higher doses.

The Global Digestive Health Market is expected to reach at a CAGR of 8.5% during the forecast period 2024-2031. The Global ...

A novel "Powder Solution Technology" involves absorption and adsorption efficiency which makes use of liquid medications, drug suspensions admixed with suitable carriers, coating materials and ...